Simaravibart
Based on 1 Customer Validation
Simaravibart (MAD-0004J08) is an IgG1κ antibody targeting the SARS-CoV2 spike (S) glycoprotein receptor binding domain.
For research use only. We do not sell to patients.
- Purity: 98.59%
- CAS No.: 2657609-23-7
- Molecular Weight:144.955 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG1 kappa
Virus
Severe acute respiratory syndrome coronavirus 2
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
43740600 [NCBI]
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized SARS-CoV-2 S Protein (Omicron, B.1.1.529, HEK293, His, HY-P74444) can bind Simaravibart. The EC50 for this effect is 927 ng/mL.
Chemical Information
-
CAS No. 2657609-23-7
-
Appearance Liquid
-
Molecular Weight 144.955 kDa
-
Color Colorless to light yellow
-
SMILES
[Simaravibart]
-
Synonyms
MAD-0004J08
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (255 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)